New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
NCT01095146 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2010-03-30
Summary
Macrophage activation syndrome(MAS) is a complication of bone marrow suppression, coagulopathy and CNS dysfunction which occurs in rheumatic diseases. Normally the (Hemophagocytic Lympho-Histiocytosis) HLH-2004 criteria is used to diagnose patients with MAS. However this criteria is probably not sensitive and would probably be fulfilled quite late into the disease. Thus there would be an unacceptable delay. Ravelli et al came up with a different set of criteria based on data of patients reported in literature.
Systemic onset juvenile idiopathic arthritis (SoJIA) is the most common cause of MAS. MAS in other rheumatic illnesses occurs in the setting on unbridled inflammation. In both SoJIA and uncontrolled rheumatic disease the patient is liable to have high WBC counts and high platelet counts. Bone marrow suppression which is one of the pathognomic features of MAS would be picked up very late if absolute cut off values were utilized. Kelly et al used the same arguments in their review to suggest that in MAS/Reactive hemophagocytic lymphohistiocytosis(ReHLH), the trend of change in laboratory parameters would be more useful than absolute cut offs. Hence the investigators propose new candidate criteria which are based on trends of laboratory parameters and seek to determine their utility in comparison to absolute cut offs of HLH or Ravelli criteria. The investigators also wanted to determine that among the Ravelli criteria and HLH-2004 criteria, which were fulfilled earlier in patients diagnosed as having MAS.
Study hypothesis:-Criteria which measure serial trend of laboratory parameters would be fulfilled earlier than absolute cut offs when diagnosing MAS in patients with rheumatic illness.
Conditions
- Macrophage Activation Syndrome
- Lymphohistiocytosis, Hemophagocytic
Sponsors & Collaborators
-
Amrita Institute of Medical Sciences & Research Center
lead OTHER
Principal Investigators
-
Sharath Kumar, MD · Amrita Institute of Medical Sciences
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2012-01-31
- Completion
- 2012-01-31
Countries
- India
Study Locations
More Related Trials
-
Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.
NCT06276036 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
NCT01400503 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
NCT02780583 ·Status: TERMINATED ·Phase: PHASE1
-
Autoreactive B Cells in Membranous Nephropathy
NCT04095156 ·Status: RECRUITING
-
Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
NCT02862054 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Biomarkers in Giant Cells Arteritis
NCT02844023 ·Status: TERMINATED ·Phase: NA
-
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
NCT02556866 ·Status: TERMINATED ·Phase: PHASE2
-
Giant Cell Arteritis - Ways to Precision Medicine
NCT07084480 ·Status: RECRUITING
-
Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
NCT00933296 ·Status: COMPLETED
-
Study of Factors Regulating Mast Cell Proliferation
NCT00044122 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
NCT01024036 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
NCT05984394 ·Status: RECRUITING
-
A Registry for Patients With Systemic Mastocytosis in China
NCT06013683 ·Status: RECRUITING
-
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
NCT00685373 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Monocyte Values Accompanied by Lymphopenia on the Prognosis of Patients Diagnosed With COVID-19
NCT06968156 ·Status: COMPLETED
-
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
NCT00246857 ·Status: RECRUITING
-
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02169219 ·Status: COMPLETED ·Phase: PHASE4
-
Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
NCT00647166 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
NCT05137496 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456 ·Status: RECRUITING ·Phase: NA
-
MoMa Signature During Granulomatosis
NCT05916638 ·Status: RECRUITING
-
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
NCT05626387 ·Status: UNKNOWN ·Phase: PHASE4
-
Characteristics of Mast Cells in Mastocytosis
NCT00001356 ·Status: COMPLETED
-
Juvenile Autoimmune Necrotizing Myopathies
NCT04295785 ·Status: UNKNOWN
-
Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome
NCT00577525 ·Status: COMPLETED